The 55% ORR in heavily pretreated gynecologic cancers significantly exceeds the 10-25% standard-of-care benchmark for PROC, suggesting potential best-in-class positioning. Monitor the June 2 KOL event for expert context and the dose-optimization data readout for confirmation of efficacy durability. The Fast Track designation supports an accelerated regulatory path.
Price Chart
Executive Summary
NextCure announced positive Phase 1 dose escalation data for SIM0505, a CDH6-targeting ADC, at ASCO 2026, showing a 55% ORR in gynecologic cancers (52.9% in ovarian, 66.7% in USC) at therapeutic doses. The data supports an ongoing dose-optimization study focused on platinum-resistant ovarian cancer, and the FDA has granted Fast Track Designation for PROC. For a $22M market cap clinical-stage biotech, this is a significant pipeline validation event.
Key Facts
- 55% ORR (11/20) in gynecologic cancers at therapeutic doses (4.8-8.0 mg/kg) per RECIST 1.1 at 12 weeks
- 52.9% ORR (9/17) in ovarian cancer; 66.7% ORR (2/3) in uterine serous carcinoma
- FDA Fast Track Designation granted for SIM0505 in platinum-resistant ovarian cancer
- Phase 1 dose optimization initiated May 2026 in PROC; global study to enroll up to 120 patients
- Favorable safety profile: Grade 3/4 TEAEs predominantly hematological and manageable; only 3 dose discontinuations due to TRAEs
- NextCure holds exclusive global rights excluding China/HK/Macau/Taiwan (retained by Simcere Zaiming)
Financial Impact
No financial data provided; clinical-stage company with no approved products or revenue
Risk Factors
- Early-stage data (Phase 1 dose escalation, n=20 evaluable at therapeutic dose) — ORR may not replicate in larger Phase 2/3 trials
- Two of nine ovarian PRs are unconfirmed or pending confirmation; durability of responses unknown
- Competing CDH6 ADCs (e.g., from other developers) could limit market share
- NextCure has no approved products and relies on partnerships and financing; cash runway not disclosed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304283 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | SC 13G | $5.44 | awaiting T+60 | — | $5.22 (−3.95%) |
Sep 25, 2026 4w ago | 425 | $5.08 | awaiting T+60 | — | $5.22 (+2.85%) |
Sep 25, 2026 4w ago | 8-K | $5.08 | awaiting T+60 | — | $5.22 (+2.85%) |
Aug 10, 2026 11w ago | 425 | $6.73 | awaiting T+60 | — | $5.22 (+22.36%) |
Aug 4, 2026 12w ago | 425 | $5.78 | awaiting T+60 | — | $5.22 (−9.60%) |
Aug 3, 2026 12w ago | Insider Buy | $5.78 | awaiting T+60 | — | $5.22 (−9.60%) |
Jul 29, 2026 12w ago | Insider Buy | $5.03 $4.98 | ▼ −0.99% | ▼ −3.46% | $5.22 (+3.88%) |
Jul 14, 2026 15w ago | 425 / 8-K | $6.58 $6.56 | ▼ −0.30% | ▼ −3.68% | $5.22 (−20.59%) |
Jul 14, 2026 15w ago | 8-K | $6.58 $6.56 | ▲ +0.30% | ▲ +3.68% | $5.22 (+20.59%) |
Jun 1, 2026 21w ago | 8-K | $3.38 $5.91 | ▲ +74.85% | ▲ +73.62% | $5.22 (+54.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers